All Stories

  1. Chronic Treatment With Ticagrelor Limits Myocardial Infarct Size

    Article • Arteriosclerosis Thrombosis and Vascular Biology, September 2014, Wolters Kluwer Health

    Sven Nylander

  2. Adenosine-Mediated Effects of Ticagrelor

    Article • Journal of the American College of Cardiology, June 2014, Elsevier

    Sven Nylander

  3. Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1

    Article • Journal of Cardiovascular Pharmacology and Therapeutics, January 2014, SAGE Publications

    Sven Nylander

  4. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism

    Article • Journal of Thrombosis and Haemostasis, October 2013, Elsevier

    Sven Nylander

  5. Reply

    Article • Journal of the American College of Cardiology, August 2013, Elsevier

    Sven Nylander

  6. High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition

    Article • Thrombosis Research, April 2013, Elsevier

    Sven Nylander

  7. TICAGRELOR-INDUCED BLEEDING IN MICE CAN BE REVERSED BY FVIIA (NOVOSEVEN®) AND FII

    Article • Journal of the American College of Cardiology, March 2013, Elsevier

    Sven Nylander

  8. REVERSAL OF TICAGRELOR-INDUCED INHIBITION OF ADP-INDUCED PLATELET AGGREGATION BY THE ADDITION OF UNINHIBITED PLATELETS IN VITRO

    Article • Journal of the American College of Cardiology, March 2013, Elsevier

    Sven Nylander

  9. Ticagrelor Enhances Adenosine-Induced Coronary Vasodilatory Responses in Humans

    Article • Journal of the American College of Cardiology, February 2013, Elsevier

    Sven Nylander

  10. Discovery of phosphoinositide 3-kinases (PI3K) p110β isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance

    Article • Bioorganic & Medicinal Chemistry Letters, November 2012, Elsevier

    Sven Nylander

  11. Human target validation of phosphoinositide 3‐kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor

    Article • Journal of Thrombosis and Haemostasis, October 2012, Elsevier

    Sven Nylander

  12. ADENOSINE MAY MEDIATE TICAGRELOR-INDUCED DYSPNEA

    Article • Journal of the American College of Cardiology, March 2012, Elsevier

    Sven Nylander

  13. Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel

    Article • Journal of Thrombosis and Haemostasis, October 2011, Elsevier

    Sven Nylander

  14. 22 Inhibition Of ADP- and thromboxane-dependent pathways of platelet aggregation by The P2Y12 antagonists, ticagrelor and prasugrel

    Article • Heart, September 2011, BMJ

    Sven Nylander

  15. Ticagrelor Effectively and Reversibly Blocks Murine Platelet P2Y 12 -Mediated Thrombosis and Demonstrates a Requirement for Sustained P2Y 12 Inhibition to Prevent Subsequent Neointima

    Article • Arteriosclerosis Thrombosis and Vascular Biology, December 2010, Wolters Kluwer Health

    Sven Nylander

  16. Evaluation of platelet function, a method comparison

    Article • Platelets, February 2006, Taylor & Francis

    Sven Nylander

  17. Characterisation of species differences in the platelet ADP and thrombin response

    Article • Thrombosis Research, January 2006, Elsevier

    Sven Nylander

  18. Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP‐ and thrombin‐induced human platelet activation

    Article • British Journal of Pharmacology, August 2004, Wiley

    Sven Nylander, Dr Sofia Ramström

  19. Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action

    Article • Blood Coagulation & Fibrinolysis, February 2003, Wolters Kluwer Health

    Sven Nylander

  20. The relative importance of the ADP receptors, P2Y12 and P2Y1, in thrombin-induced platelet activation

    Article • Thrombosis Research, January 2003, Elsevier

    Sven Nylander, Dr Sofia Ramström

  21. Effect of Different Types of Thrombin Inhibitors on Thrombin/Thrombomodulin Modulated Activation of Protein C In Vitro

    Article • Thrombosis Research, December 2001, Elsevier

    Sven Nylander, Johanna Deinum

  22. Brefeldin A, but not monensin, completely blocks CD69 expression on mouse lymphocytes:

    Article • Journal of Immunological Methods, April 1999, Elsevier

    Sven Nylander

  23. 3.P.393 Immunological characterisation of mice lacking functional LDL receptors and apoE

    Article • Atherosclerosis, October 1997, Elsevier

    Sven Nylander